Chronic stable angina overview

Jump to navigation Jump to search
https://https://www.youtube.com/watch?v=zD9aXZY0pdY%7C350}}

Chronic stable angina Microchapters

Acute Coronary Syndrome Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Classic
Chronic Stable Angina
Atypical
Walk through Angina
Mixed Angina
Nocturnal Angina
Postprandial Angina
Cardiac Syndrome X
Vasospastic Angina

Differentiating Chronic Stable Angina from Acute Coronary Syndromes

Pathophysiology

Epidemiology and Demographics

Risk Stratification

Pretest Probability of CAD in a Patient with Angina

Prognosis

Diagnosis

History and Symptoms

Physical Examination

Test Selection Guideline for the Individual Basis

Laboratory Findings

Electrocardiogram

Exercise ECG

Chest X Ray

Myocardial Perfusion Scintigraphy with Pharmacologic Stress

Myocardial Perfusion Scintigraphy with Thallium

Echocardiography

Exercise Echocardiography

Computed coronary tomography angiography(CCTA)

Positron Emission Tomography

Ambulatory ST Segment Monitoring

Electron Beam Tomography

Cardiac Magnetic Resonance Imaging

Coronary Angiography

Treatment

Medical Therapy

Revascularization

PCI
CABG
Hybrid Coronary Revascularization

Alternative Therapies for Refractory Angina

Transmyocardial Revascularization (TMR)
Spinal Cord Stimulation (SCS)
Enhanced External Counter Pulsation (EECP)
ACC/AHA Guidelines for Alternative Therapies in patients with Refractory Angina

Discharge Care

Patient Follow-Up
Rehabilitation

Secondary Prevention

Guidelines for Asymptomatic Patients

Noninvasive Testing in Asymptomatic Patients
Risk Stratification by Coronary Angiography
Pharmacotherapy to Prevent MI and Death in Asymptomatic Patients

Landmark Trials

Case Studies

Case #1

Chronic stable angina overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic stable angina overview

CDC onChronic stable angina overview

Chronic stable angina overview in the news

Blogs on Chronic stable angina overview

to Hospitals Treating Chronic stable angina overview

Risk calculators and risk factors for Chronic stable angina overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-In-Chief: Maheep Singh Sangha, M.B.B.S.; Cafer Zorkun, M.D., Ph.D. [4] Muhammad Saad, M.B.B.S.[5]

Overview

Angina pectoris, commonly known as angina, is chest pain[1] due to ischemia (a lack of blood and subsequent lack of oxygen supply) of the heart muscle. It is most often due to obstruction or spasm of the coronary arteries (the heart's blood vessels). Coronary artery disease, also referred to as atherosclerosis of the coronary arteries, is the most common cause of angina. The term derives from the Greek ankhon ("strangling") and the Latin pectus ("chest") meaning "a strangling feeling in the chest". In angina pectoris, symptomatic onset may include chest discomfort indicated by a feeling of tightness, heaviness, or pain in the chest cavity.

Historical Perspective

Chronic stable angina is a form of chest pain characterized by an insufficient blood flow to the myocardium of the heart to match myocardial energy demands (ischemia). The term angina was originally derived from the Greek word ankhon and the Latin word pectus, which when combined, loosely translates as "a strangling feeling in the chest". Attempts to classify this disease state began as early as the 4th century B.C., when Lucius Annaeus Seneca first described the symptoms he was experiencing as "to have any other malady is to be sick; to have this is to be dying". Throughout history many renowned researchers and health care professionals have contributed to the understanding, definition, and recognition of angina.

Classification

Chronic Stable Angina

Angina pectoris is a sensation of chest discomfort that is often described as: a feeling of tightness, heaviness, or pain. Angina pectoris is a characteristic of coronary heart disease. When it occurs chronically, this is referred to as stable angina.

Walk Through Angina

Walk through angina is the appearance of anginal chest discomfort early in the course of exertion which subsequently subsides despite continued exertion.

Mixed Angina

Mixed or variable threshold angina pectoris is a syndrome in which there is substantial variation in the magnitude of physical activity that induces anginal chest pain.

Nocturnal Angina

Nocturnal angina is the occurrence of anginal discomfort either during the first hours of sleep or during the early morning hours. It is speculated that discomfort caused during the first hours of sleep is due to increased venous return, whereas the discomfort caused during the early morning hours is due to increased vascular tone.

Postprandial Angina

Postprandial angina pectoris is anginal chest discomfort that occurs following meals. It is thought to be due to an increase in vascular tone or a reduction in coronary blood flow.

Cardiac Syndrome X

Cardiac syndrome X is angina associated with objective evidence of myocardial ischemia in the absence of epicardial coronary artery disease. Syndrome X has been hypothesized to be a disorder of the coronary microvasculature rather than the large caliber epicardial coronary arteries.

Vasospastic Angina

Coronary vasospasm is a multi-factorial, transient, and abrupt reduction of luminal diameter of an epicardial coronary artery due to inappropriate constriction of coronary smooth muscle that can generate distal ischemia. This may occur spontaneously or in the context of angioplasty, particularly if denudation of the endothelium or dissection occurs. In addition, the vasospasm can either be focal or multifocal (which compromises more than one vessel).

Differentiating Chronic Stable Angina from Urgent Conditions

Stable angina must be differentiated from unstable angina and acute coronary syndromes. If the pattern of angina is stable, this is termed chronic stable angina. If the magnitude, threshold or frequency of chest pain accelerates, this is termed an acute coronary syndrome.

Pathophysiology

The primary causes of myocardial ischemia in chronic stable angina are: fixed epicardial stenosis, spasm of the epicardial artery and/or microvascualar disease. The causation of angina is not mutually exclusive. Two or more causes may coexist in the same patient.

Epidemiology and Demographics

Coronary artery disease (CAD) remains the single leading cause of death in the United States. Stable angina is the initial manifestation of ischemic heart disease in approximately 50% of these patients.

Risk Stratification

The average mortality in patients with stable angina ranges from 1-3%. However, the prognosis varies widely depending on various factors such as: the duration and severity of symptoms, resting ECG abnormalities, abnormal left ventricular function and associated comorbidities.[2]

Pretest Probability

Pretest probability is defined as the probability of the target disorder before the result of a diagnostic test is known. A number of studies have emphasized the importance of pretest probability of coronary artery disease (CAD).[3] Once a thorough patient history and physical examination is complete, it is important to assess the probability of underlying CAD, as this helps both the physician and the patient to determine the next step in the diagnosis and treatment. In patients with chronic stable angina, the strongest predictors contributing to underlying significant CAD include: the age, gender and type of pain (typical, atypical) experienced.[3]

Prognosis

Ischemic heart disease remains as the number one cause of mortality in developed countries. The prognosis of stable angina varies widely depending on severity of symptoms, extent of atherosclerosis and presence of other risk factors and co-morbidities. The presence of impaired left ventricular function is associated with a poor prognosis. Reduced LV function, number and location of stenoses, workload in METs calculated using Duke score are the strongest predictors of survival in patients with chronic stable angina.

Diagnosis

History and Symptoms

The name 'angina pain' can be thought of as a misnomer as patients often describe the sensation as discomfort rather than physical pain. The best method to characterize this discomfort/pain is through the 'PQRST system'.

Physical Examination

Among patients with chronic stable angina, the physical examination may be asymptomatic or characteristically normal. Patients that present with left ventricular dysfunction are associated with a poorer prognosis than patients who do not present with dysfunction. All patients should be examined carefully for the presence of rales and other signs of heart failure. The majority of patients present with history of either, chest pain or discomfort categorized as: typical or atypical. Typical presentation would include pain or discomfort in the front or anterior precordium. Atypical presentation can be more convoluted in presentation and involve a wide range of symptoms. For example, an atypical patient may present with dyspnea instead of chest pain and this is termed an angina equivalent. In addition to the historical presentation of chest pain or discomfort, the patient history should be extensively evaluated to include an assessment of cardiovascular risk factors. Physical examination may be normal or asymptomatic. In some cases, a physical examination may reveal heart failure. Additional findings can be important in understanding the onset of the condition. For instance, the presence of peripheral vascular disease may be associated with an increased risk of coronary artery disease (CAD).

Test Selection Guideline for the Individual Basis

Criteria for test selection hinges largely on the current disease state of the individual patient and subsequent level of fitness for testing. Potential diagnostic testing modalities include: exercise ECG, ECG at rest, exercise echocardiography, echocardiography at rest, and stress scintigraphy.

Laboratory Findings

In patients with chronic stable angina, initial laboratory investigations are used to: identify potential causes of ischemia, establish risk factors, and determine the overall prognosis for the patient. An initial laboratory test can provide a wide variety of clinical information. For instance, low hemoglobin levels can cause ischemia. Therefore, assessing hemoglobin as a part of complete blood count provides prognostic information.[4] Biomarkers, such as troponin and CK-MB, are used to exclude myocardial injury. In assessment for risk factor stratification, all patients with ischemic heart disease are recommended to have a a standard round of blood work conducted including fasting plasma glucose levels and a complete lipid profile. Serum creatinine[5] is used to assess renal dysfunction[6] due to associated hypertension or diabetes and remains a negative prognostic factor. In patients with chronic stable angina, an elevation in fasting glucose[7] independently predicts the adverse outcome. Recent research on NT-pro-BNP has demonstrated the ability to predict long-term mortality in patients with chronic stable angina independent of age, ventricular ejection fraction and other risk factors.[8]

Electrocardiography

A resting 12-lead ECG is performed and recorded in all patients with suspected angina pectoris. However, a normal resting ECG does not exclude the diagnosis of ischemia. Abnormalites commonly observed on resting ECG include: ST-segment changes, left ventricular hypertrophy (LVH), left branch bundle blockage (LBBB), signs of coronary artery disease (CAD) such as previous myocardial infarction (MI) or abnormal repolarization patterns.[9] An ECG recorded during pain helps to identify an underlying vasospasm.

Exercise EKG

In patients with chronic stable angina, exercise ECG is more sensitive and specific to identify inducible ischemia and to diagnose coronary artery disease.[10] ECG abnormalities associated with MI include: down sloping of ST-segment depression or elevation, accompanying angina that occurs at a low workload during early stages of exercise and persistent for more than 3-minutes after exercise. The reliability of diagnosis is shown to improve with the evaluation of ST changes in relation to heart rate.[11] Bruce protocol or treadmill (expressed in terms of METs) or bicycle ergometer (expressed in terms of watts) are used to detect MI. Exercise ECG test must be terminated on the achievement of maximal predicted heart rate and/or if the patient becomes symptomatic or develops pain with significant ST-segment changes. Exercise ECG test also provides prognostic stratification to evaluate the response to medical therapy or revascularization.[12]

Chest X-Ray

Routine chest x-ray examination is important in the evaluation of patients with signs or symptoms of congestive heart failure,[13] valvular heart disease, pericardial disease, or aortic dissection/aneurysm. The presentation of cardiomegaly, characterized by pulmonary congestion on a chest x-ray, is indicative of a poor prognosis for the patient.[14]

Myocardial Perfusion Scintigraphy with Pharmacologic Stress

Pharmacologic stress testing using myocardial perfusion scintigraphy or echocardiography can be employed in patients with known or suspected angina pectoris who are unable to perform adequate exercise tests. These patients often owe their ineligibility status to associated conditions such as: peripheral vascular disease, musculoskeletal disorders, diseases of the lower extremities, severe obesity, or deconditioning. Pharmacologic stress testing is achieved with the infusion of either dobutamine in incremental dose, which acts by increasing myocardial oxygen consumption and thereby mimic effect of exercise, or with the use of coronary vasodilators such as adenosine or dipyridamole, which acts by differentiating regions based on perfusion. Stress imaging is of great value in the evaluation of patients with low pretest probability of CAD.[15] However, in patients with LBBB, perfusion scintigraphy is shown to have poor diagnostic accuracy.[16]

Myocardial Perfusion Scintigraphy with Thallium

In patients with baseline ECG abnormalities,a myocardial perfusion test can be used to localize the region of ischemia. Thallium-201 and technetium-99m are the two radio-labeled agents that are frequently used for the assessment of myocardial perfusion. Myocardial uptake of thallium-201 chloride is directly proportional to the regional myocardial blood flow and is dependent on the presence of viable myocardium. In patients with known CAD, a normal thallium stress test without a perfusion defect is indicative of a benign process and associated with excellent prognosis. Patients with a normal thallium scan are at low risk for CAD and subsequent coronary angiography is indicated only if the patient has a high probabilty Duke treadmill score. Contraindications for thallium stress test include the presence of arrhythmia, acute myocarditis, severe aortic stenosis and acute MI within the past 2 days.

Echocardiography

Echocardiography is useful to evaluate ventricular function[17] and detect ischemia induced regional wall motion abnormality that occurs at rest, during exercise or with pharmacologic stress test. As a testing modality, two-dimensional echocardiography is often coupled with other testing modalities to detect regional wall motion abnormalities that most frequently occur during induced myocardial ischemia associated with coronary artery disease (CAD). Potential paired testing modalities include: upright treadmill exercise, supine bicycle ergometry, pacing, and pharmacologic stress, particularly with dobutamine. Patients with CAD may respond more adversely to testing modalities than their counterparts. Often, an adverse outcome such as the inability to perform a bicycle ergometry test or exercise treadmill protocol can be characterized as a poor prognostic factor.

Exercise Echocardiography

Stress echocardiography is echocardiography that is paired with different forms of stressors, such as exercise or pharmacological. Exercise stress echocardiography is the preferred stress echocardiography modality. However, it is not suitable for all patients and may not be feasible in populations that do not meet a minimum level of fitness. In patients who are ineligible for exercise stress echocardiography, pharmacological stress echocardiography can be a useful alternative. Common pharmacological stressors include: adenosine, dipyridamole, and dobutamine. As a testing modality, exercise echocardiography is noted as more sensitive, more specific and has a higher predictive value than exercise ECG. Exercise echocardiography can be helpful in the evaluation of regional wall motion response, location and extent of ischemia during stress in patients with MI. During exercise, the normal myocardium is hyperdynamic while in patients with MI, the ischemic myocardium is either akinetic or hypokinetic.

Positron Emission Tomography

Positron emission tomography is of particular value in the assessment of regional coronary blood flow reserve, myocardial perfusion, and the presence and extent of hibernating myocardium.

Ambulatory ST Segment Monitoring

Ambulatory ECG monitoring (Holter monitor) is used to detect major arrhythmias and myocardial ischemia occurring during normal activities. Ambulatory ECG monitoring adds very little prognostic value in patients with chronic stable angina, however, does play a role in the detection of major arrhythmias in patients with chronic stable angina and suspected vasospastic angina.

Electron Beam Tomography

The extent of coronary artery calcification directly correlates to the area of atheromatous plaque.[18] Hence in patients with chest pain, coronary artery calcium (CAC) scoring is one of the factor to be considered in the risk assessment for coronary artery disease. The methods used for detection and quantification of CAC include electron beam computed tomography (EBCT) and multi-detector computed tomography (MDCT).[19] Agatston score is a computed software that is commonly used to measure CAC based on the density and area of calcified plaques.[20]

Cardiac Magnetic Resonance Imaging

Cardiac magnetic resonance imaging (CMRI) is a non-invasive test that is useful in the evaluation of overall coronary anatomy and function. CMRI also helps in the identification of inflammation,[21] neovascularization[22] and fibrous cap.[23] It, therefore, holds the potential for plaque characterization.

Coronary Angiography

Coronary angiography is a gold standard test in the evaluation of severity of coronary artery disease and the possibility for revascularization. Coronary angiography is indicated in patients with a high pretest probability of CAD and in symptomatic patients with inconclusive initial noninvasive tests. Provocative testing with ergonovine during angiography may be useful in patients with vasospastic angina. Major complications such as death, MI and stroke associated with routine angiography is as low as 0.1% - 0.2%.[24]

Treatment

Treatment of chronic coronary disease/chronic coronary syndromes aims to minimize symptoms and improve quality of life, and to reduce cardiovascular events through guideline-directed secondary prevention therapies.[25][26] Treatment includes lifestyle modification, event-preventing GDMT (antithrombotic therapy, intensive lipid lowering, BP/diabetes therapies, and selected cardiometabolic agents), antianginal drugs for symptom control, and revascularization when indicated.[25][26]

Initial management is GDMT, with revascularization considered for

(1) unacceptable angina/ischemia despite optimized medical therapy, and/or

(2) selected patients with high-risk anatomy/physiology where revascularization may reduce spontaneous MI and cardiovascular death during long-term follow-up.

The choice of PCI versus CABG should be individualized using a Heart Team approach based on coronary anatomy/complexity (including left main and multivessel disease), LV function, diabetes, bleeding/ischemic risk, and likelihood of complete revascularization.[25][26]

Pharmacotherapy

Pharmacotherapy includes (a) antianginal therapy for symptom relief and (b) secondary-prevention GDMT to reduce cardiovascular events.[27][28] Mainstays include patient education, lifestyle changes, and GDMT. For angina relief, either a beta-blocker or a calcium-channel blocker is recommended as first-line therapy; long-acting nitrates and other agents may be added if symptoms persist or first-line therapy is not tolerated[27][28] In patients with chronic stable angina, immediate symptomatic relief is achieved with short-acting sublingual nitrates and long term symptom relief is achieved with beta blockers as first line therapy, or calcium channel blockers and long-acting nitrates when beta blockers are contraindicated. Event-preventing therapies include antiplatelet therapy and intensive lipid lowering for most patients; ACEi/ARB is recommended when indicated (e.g., hypertension, diabetes, CKD, or LV systolic dysfunction). Long-term beta-blocker therapy is not recommended solely to improve outcomes in CCD in the absence of MI within the past year, LVEF ≤50%, or another primary indication.[27][29]

Anti-platelet Agents

Aspirin

In patients with ischemic heart disease, prophylactic low dose aspirin A single antiplatelet agent (aspirin or clopidogrel) is generally recommended long term in CCS patients with obstructive atherosclerotic CAD, with choice individualized to ischemic and bleeding risk.[28]

Dipyridamole

Dipyridamole is a pyrimidopyrimidine derivative with poor anti-thrombotic efficacy and therefore not recommended for anti-platelet therapy in patients with chronic stable angina.[30] Dipyridamole may also exacerbate anginal symptoms due to coronary steal phenomenon.[31]

Clopidogrel

Thienopyridines, such as clopidogrel and ticlopidine, selectively inhibit ADP-induced platelet aggregation and are used as an alternative to aspirin in patients with significant risk of arterial thrombosis.

Anti-anginal Agents

Nitrates

Short-acting nitrates provide rapid symptom relief and can be used for situational prophylaxis; long-acting nitrates are used for ongoing symptom control as add-on therapy when first-line agents are insufficient or not tolerated.[27][28] Organic nitrates are therapeutic precursors of endothelium-derived relaxing factor that produce their beneficial effects both, by decreasing myocardial oxygen requirements and by improving myocardial perfusion. The most commonly used nitrates are nitroglycerin, isosorbide dinitrate and isosorbide mononitrate. Short acting nitrates, such as sublingual nitroglycerin, are best suited to treat acute episodes of angina and are effective when used for situational prophylaxis. Long-acting nitrates help to reduce the frequency and severity of angina and may increase exercise tolerance in patients with stable angina.[32][33][34] Nitrates at therapeutic doses do not affect coronary vascular resistance, consistent with the use of dipyridamole and other short acting dihydropyridines.

Beta Blockers

In patients with stable angina, beta blockers are used as a first line of therapy for both, symptomatic relief[35][36][37] Beta-blockers are effective for symptom relief; long-term beta-blocker therapy is not recommended to improve outcomes in CCD in the absence of MI in the past year, LVEF ≤50%, or another primary indication (e.g., arrhythmia or uncontrolled hypertension).[27][38] The physiologic mechanism of benefit of this therapy is a marked reduction in myocardial oxygen consumption by reducing the heart rate and myocardial contractility. Selective beta-1 blockers are preferred to non-selective beta-blockers due to fewer associated side effects.[34] When LV systolic dysfunction is present (LVEF <50%), use evidence-based beta-blockers (metoprolol succinate, carvedilol, or bisoprolol) in preference to other beta-blockers.[29]In patients started on beta-blockers after MI who have no current LVEF ≤50%, angina, arrhythmia, or uncontrolled hypertension, reassessment of the need for therapy beyond 1 year may be reasonable.[29]

Calcium Channel Blockers

Calcium-channel blockers are first-line antianginal therapy (alternative to beta-blockers) and are particularly useful for vasospastic angina.[27][28]Avoid verapamil and diltiazem in HFrEF due to increased heart-failure events. The beneficial anti-anginal effects of CCB include: reduction in the afterload consequent to systemic vasodilation as well as epicardial vessel vasodilation, enhancement of the coronary collateral flow with subsequent sub-endocardial perfusion due to the inhibition of calcium influx via L-type channels.[39] Long-acting calcium channel blockers are an effective antianginal agent and are considered to be the first choice in post-MI patients with a contraindication to beta-blocker.[40] Long-acting CCBs are also specifically used to control symptoms in patients with vasospastic angina.[41] However short-acting CCBs, such as nifedipine, are avoided due to an increased risk of myocardial infarction and mortality.[42][36][37]

Potassium Channel Openers

Nicorandil has both, anti-anginal effects due to nitrate-like and ATP-sensitive potassium channel activating properties and nicorandil can be used as add-on/alternative antianginal therapy when beta-blockers/CCBs are insufficient or not tolerated (availability varies by country).[28] Therefore, nicorandil usage in addition to standard anti-anginal therapy may be indicated in patients who are intolerant to beta-blocker therapy or in whom CCB monotherapy or combination therapy CCB is unsuccessful.[43][44][45].

Newer Anti-anginal Agents

Ranolazine is a one of the newer FDA approved anti-anginal medication for management of chronic stable angina. Perhexiline is another anti-anginal, primarily used in Australia and New Zealand, being studied for use in the United States and UK. In patients with chronic stable angina, other effective agents with anti-anginal and anti-ischemic properties are ivabradine, trimetazidine and molsidomine.Antianginal drugs are primarily for symptom relief and generally do not reduce MACE; selection and combination should be individualized to haemodynamics (HR/BP), comorbidities, and tolerability.Ivabradine should not be combined with verapamil or diltiazem and is mainly considered in selected patients with LV systolic dysfunction.[28]


ACEI/RAAS Blockers

ACE inhibitor/ARB therapy is recommended in CCD when indicated (e.g., hypertension, diabetes, CKD, or LV systolic dysfunction) as part of event-preventing GDMT.[46][47][48] Based on the recent AHA and ESC guidelines, the recommended goal blood pressure in patients with atherosclerotic coronary vascular disease is less than 130/80 mm Hg.[49][45][50]

Anti-lipid Agents

Statins by inhibiting HMG-CoA reductase subsequently reduce serum cholesterol levels and have been shown to be effective in the primary prevention of various hyperlipidemias and secondary prevention of ischemic heart disease.[51][52] The most commonly used statins are simvastatin, atorvastatin, pravastatin and rosuvastatin.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.] Lancet 361 (9364):1149-58. DOI:10.1016/S0140-6736(03)12948-0 PMID: 12686036</ref>[53]Statins are first-line lipid-lowering therapy in CCD/CCS; adjunctive agents (ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran) may be used in select populations to further lower LDL-C, noting that clinical outcomes data are unavailable for some newer agents such as inclisiran. [27]

Revascularization

The goal of the treatment of chronic stable angina is to reduce the symptoms, delay the progression of atherosclerosis, and prevent cardiovascular events. In order to achieve these goals, lifestyle modifications and medical therapy are the first line treatment. Revascularization is done to increase survival in specific conditions where the stenosis of the coronary arteries is anatomically and functionally significant and the symptoms are refractory to medical therapy. There are currently two well-established revascularization approaches for the treatment of chronic stable angina caused by coronary atherosclerosis: CABG and PCI. Since the introduction of coronary artery bypass surgery in 1967 and percutaneous transluminal coronary angioplasty (PTCA) in 1977, research has supported the effective usage of both strategies for treatment of patients with chronic stable angina. However, as with any treatment method, both methodologies have weaknesses. The choice between PCI and CABG is based upon anatomy and other factors such as left ventricular function and the presence or absence of diabetes. Selection of PCI vs CABG should be individualized using a Heart Team approach based on coronary anatomy and complexity (including left main and multivessel disease), diabetes, LV function, and feasibility of complete revascularization.[54][28]When invasive angiography is performed, invasive functional assessment (FFR/iFR) is recommended for intermediate stenoses to guide revascularization decisions.

PCI

Percutaneous coronary intervention (PCI) is performed to relieve angina/ischemia and, in selected higher-risk obstructive CAD, to reduce long-term spontaneous MI and cardiac death.[27][28]For angiographically intermediate stenoses, invasive physiology with FFR or iFR is recommended to guide PCI decisions; PCI should not be performed when FFR is >0.80 or iFR is >0.89 because outcomes with medical therapy alone are favorable.[54]Revascularization generally provides greater improvement in angina and quality of life than medical therapy alone, and placebo-controlled data confirm angina relief from PCI in patients with stable angina and ischemia.

CABG

Coronary artery bypass grafting (CABG) is preferred for prognosis in significant left main disease and for many patients with complex multivessel CAD, particularly when complete revascularization by PCI is unlikely; Heart Team selection is recommended when the optimal strategy is unclear.[27][54]

PCI vs Medical Therapy

An increased risk of mortality and morbidity is associated with untreated coronary artery disease.[55] The main aim of therapy in patients with chronic stable angina is to alleviate symptoms, delay the progression of atherosclerosis, reduce the incidence of adverse coronary events and improve prognosis. This may be achieved with either initial medical therapy or with initial revascularization that includes percutaneous coronary intervention or coronary artery bypass grafting. Medical therapy alleviates symptom and improves prognosis; however, on the contrary, PCI improves angina and quality of life, while effects on survival are nuanced and depend on anatomy, ischemic burden, LV function, and comorbidities; overall, many CCD trials show no all-cause mortality reduction with routine revascularization, with important exceptions (e.g., CABG in left main disease and in severe LV dysfunction).[27][28][54]In FAME 2 (NEJM RCT; 888 randomized), FFR-guided PCI vs medical therapy reduced the composite of death/MI/urgent revascularization at 5 years (13.9% vs 27.0%, HR 0.46, P<0.001), driven mainly by fewer urgent revascularizations (6.3% vs 21.1%, HR 0.27) with no significant difference in death (5.1% vs 5.2%) and a borderline MI reduction (8.1% vs 12.0%, HR 0.66, 95% CI 0.43–1.00.[56]At median 11.2 years in long-term follow-up (748 randomized with extended follow-up), FFR-guided PCI reduced the composite hierarchical endpoint (33.6% vs 41.3%; win ratio 1.25, 95% CI 1.01–1.56, P=0.043) with no all-cause death difference (win ratio 0.88, 95% CI 0.66–1.17).[57]

CABG vs Medical Therapy

CABG improves survival compared with medical therapy in significant left main disease and in selected patients with CCD and severe LV dysfunction (especially LVEF ≤35%); benefits are less consistent in patients with normal LV function and without left main/proximal LAD high-risk anatomy.[27][54][58] However, the long term benefit of CABG is limited by the progression of atherosclerosis in other unbypassed vessels and stenosis of the graft itself.

PCI and CABG vs Medical Therapy

Older revascularization trials predate contemporary GDMT and contemporary stent/physiology-guided strategies; current decisions should be guided by anatomy/complexity, ischemia/physiology, symptoms on optimized GDMT, and Heart Team discussion.[27][28][59][60] However, there are a few reservations to the application of results from these studies as they did not include the current optimal strategies of therapy.

PCI vs CABG

PCI and CABG have become the standard of care in the management of patients with symptomatic coronary artery disease. Patients with multi-vessel disease[28][54], PCI vs CABG choice depends on anatomic complexity, diabetes, LV function, and completeness of revascularization; Heart Team evaluation is recommended when strategy is unclear

Alternative Therapies for Refractory Angina

Transmyocardial Revascularization (TMR)

As the survival of patients with primary coronary events continue to increase, the number of patients presenting with refractory ischemia despite maximal medical therapy and unsuitable for further traditional revascularization techniques also continues to rise.[61] Transmyocardial revascularization (TMR) is one of the emerging techniques that has been studied in many randomized trials and has shown to reduce the incidence of recurrent angina, increase exercise tolerance time and improve quality of life.[61][62] TMR can be performed using either a laser beam or a percutaneous approach. However, only laser TMR is currently FDA approved.

Spinal Cord Stimulation (SCS)

In patients with refractory angina, spinal cord stimulation (SCS) is used to provide analgesia in the region of radiation of anginal-pain with the help an implanted device consisting of a stimulating electrode tip that extends into the dorsal epidural space, usually at the C7-T1 level.

Enhanced External Counter Pulsation (EECP)

Enhanced external counter pulsation (EECP) is another alternative therapy in the management of refractory angina. Most data from observational studies have demonstrated significant improvement in the exercise tolerance and reduction in the frequency of anginal symptoms as well as the use of nitroglycerin among patients treated with EECP.[63]

Discharge Care

Patient Follow-Up

Ongoing follow-up of the patient with chronic stable angina is necessary to monitor symptoms and to optimize antianginal therapy. It is generally recommended that these patients be evaluated every 4-6 months during first year of diagnosis/initiation of therapy and annually thereafter. Based upon clinical judgement, if the patient is poorly responsive to therapy, if the episodes are severe or frequent, or if the patient is fragile with multiple co-morbidities, they may need to be seen more frequently.

During a follow-up visit, the patient should be asked about the frequency and severity of their anginal symptoms, their level of exercise capacity, whether they have been able to modify his/her risk factors, how well they are tolerating and complying with the therapy and whether he/she has developed new illnesses or co-morbidities.Routine functional testing is not recommended for asymptomatic post‑PCI patients.[28]

Rehabilitation

Cardiac rehabilitation (CR) is a comprehensive outpatient secondary-prevention intervention combining supervised exercise training, education, risk-factor management, psychosocial support, and medication optimization to improve functional capacity and quality of life and reduce morbidity and cardiovascular mortality.[64][65]CR should be prescribed for eligible patients with chronic coronary disease, including those with stable angina and those after MI, PCI, or CABG, ideally before discharge or at the first outpatient visit.[66]Home-based CR is a reasonable alternative to center-based CR for clinically stable patients who cannot attend in-person programs, with similar short-term improvements in functional status and quality of life.[67][68] The main goal of rehabilitation is to help patients understand their disease and inculcate a regimen to stabilize and reduce, or even reverse the progression of cardiovascular disease. Cardiac rehab is often divided into phases that involve monitored exercise, counseling, emotional support, and education about lifestyle changes to reduce the risks of heart problems. It also helps reverse limitations experienced by patients who have suffered the adverse patho-physiologic and psychological consequences of cardiac events, thus, also helping patients to return to work early. Eligibility and exercise prescription should be individualized using baseline clinical assessment and exercise testing when feasible.[69] However, rapid evolution in the management of CAD has now changed the demographics of the patients, so that, even patients with recent revascularization can be candidates for rehabilitation training.

Secondary Prevention

Smoking Cessation

The 1989 Surgeon General’s report, which assessed numerous case-control and cohort studies, reported that smoking increased cardiovascular disease mortality by 50%.[70] Cigarette smoking, likely due to the hemodynamic consequences of sympathetic neural stimulation and systemic catecholamine release, plays an important role in the pathogenesis of coronary artery disease. Cigarette smoking also forms a major risk factor for acute cardiovascular events as it relates to an associated increase in blood coagulability.[71] Hence, cigarette smoking is an important reversible risk factor in the pathogenesis of CAD and cessation of which improves prognosis and is associated with a substantial decrease in the risk of mortality.[72][73][74] In patients with stable angina pectoris, nicotine replacement therapy has shown to be potentially beneficial despite the associated cardiovascular risks of nicotine, such as increase in heart rate with a small rise in blood pressure. Pharmacotherapy for tobacco cessation (including nicotine replacement) should be individualized based on clinical stability and comorbidities.[27][71] Additionally, nicotine patches have been used successfully in high-risk patients without any adverse effects such as aggravation of MI or arrhythmia.[75][76]

Weight Management

Obesity is directly associated with the development of coronary artery disease (CAD) risk factors such as: hypertension, diabetes, reduced levels of HDL-C and elevated levels of triglyceride. Research has demonstrated that CAD risk factors contribute to a strong, graded, J-shaped univariable relationship between BMI and cardiovascular disease mortality. This increased mortality, when adjusted for age, self-reported smoking status, total cholesterol, and systolic blood pressure, maintained significant hazard ratios.[77] Hence, in obese patients with CAD, weight reduction and/or dietary interventions may be warranted to reduce the incidence of above-mentioned risk factors and prevent future coronary events. Weight reduction is strongly recommended in patients with a BMI greater than 30 kg/m2 and in patients with increased waist circumference (greater than 102 cms for men and 89 cms for women), characteristic of truncal obesity.[49] Based on the plasma lipid abnormalities, adequate dietary modification may also be indicated.[78]

Physical Activity

Based on an individual's ability to exercise and severity of the symptoms, physical activity may be indicated as a treatment. As a treatment, increased physical activity has demonstrated improvements in an individual's sustained exercise duration, reduced the frequency of symptoms and also provided beneficial effects on blood pressure, diabetes and the overall lipid profile. For CCD patients without contraindications, an exercise regimen is recommended, targeting ≥150 minutes/week moderate-intensity aerobic activity or ≥75 minutes/week vigorous aerobic activity (or equivalent), plus resistance training on ≥2 days/week; intensity should be individualized and may be guided by exercise testing when available.[27][28][79]Exercise is contraindicated in unstable/refractory angina, decompensated heart failure, high-grade arrhythmias, active thromboembolic disease, or other unstable severe noncardiac illness.

Lipid Management

In patients with established coronary artery disease, in ESC CCS guidance, LDL-C goal for very-high-risk ASCVD is <55 mg/dL (<1.4 mmol/L) and ≥50% reduction from baseline; consider <40 mg/dL (<1.0 mmol/L) for recurrent vascular events within 2 years on maximal therapy.[28][49] In patients with CAD, a fasting lipid-profile may be repeated at 5 year intervals to assess the overall risk of cardiovascular mortality and morbidity.[80] Based on the individual’s lipid abnormalities, necessary dietary interventions and/or lipid-lowering agents are suggested to prevent the risk of future coronary events.[78] A Mediterranean diet consisting of fruits, vegetables, lean meat and fish has also been shown to be beneficial. Nonprescription or dietary supplements (including fish oil/omega‑3 fatty acids and vitamins) are not recommended for reducing cardiovascular events in CCD.[27][81][82][83][84] Fish consumption once a week has also been associated with reduced risk of mortality from coronary artery disease and, for this reason, is strongly recommended.[85][86]

BP Control

The risk of progression of atherosclerosis is proportional to the increase in elevated blood pressure, hyperglycemia and dyslipidemia. Therefore, the control of hypertension, hyperglycemia and other features of metabolic syndrome deserves special attention in the prevention of mortality and morbidity due to coronary artery disease. In patients with established CAD, concomitant diabetes and/or renal dysfunction, blood pressure control to <130/<80 mm Hg is a CCD performance-measure target; therapy should be individualized to overall risk and tolerability.[46][80][87] Close monitoring and lifestyle changes may be indicated in low-risk patients without documented target organ damage. However, in high-risk patients with a sustained SBP of ≥140 mm Hg and/or DBP ≥90 mm Hg, the goal is to lower blood pressure less than 140/90 with the help of combined drug therapy and life style modification. Anti-hypertensive therapies that have shown to significantly reduce cardiovascular mortality and morbidity in patients with coronary artery disease include diuretics, beta-blockers, ACEIs, ARBs and calcium channel blockers.

Diabetes Control

Diabetes is one of the major modifiable risk factors for coronary artery disease. Maintaining a good glycemic control has been demonstrated to delay the disease progression in patients with impaired glycemic control and further prevent microvascular complications.[87][88][89] In type 1 diabetics, appropriate insulin therapy and concomitant dietary modification may be required. However, in patients with type 2 diabetes, a multi-factorial intervention involving increased physical activity, weight reduction, dietary modification and/or drug therapy in CCD with type 2 diabetes, use of SGLT2 inhibitors and/or GLP‑1 receptor agonists with proven cardiovascular benefit is recommended for select groups, including some patients without diabetes depending on indication.[46][80][90]

References

  1. ↑ "MerckMedicus : Dorland's Medical Dictionary". Retrieved 2009-01-09.
  2. ↑ Daly CA, De Stavola B, Sendon JL, Tavazzi L, Boersma E, Clemens F et al. (2006) Predicting prognosis in stable angina--results from the Euro heart survey of stable angina: prospective observational study. BMJ 332 (7536):262-7. DOI:10.1136/bmj.38695.605440.AE PMID: 16415069
  3. ↑ 3.0 3.1 Diamond GA, Forrester JS (1981) Improved interpretation of a continuous variable in diagnostic testing: probabilistic analysis of scintigraphic rest and exercise left ventricular ejection fractions for coronary disease detection. Am Heart J 102 (2):189-95. PMID: 7258092
  4. ↑ Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR et al. (2005) Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 45 (10):1638-43. DOI:10.1016/j.jacc.2005.02.054 PMID: 15893180
  5. ↑ Shlipak MG, Stehman-Breen C, Vittinghoff E, Lin F, Varosy PD, Wenger NK et al. (2004) Creatinine levels and cardiovascular events in women with heart disease: do small changes matter? Am J Kidney Dis 43 (1):37-44. PMID: 14712425
  6. ↑ Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA et al. (2003) Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41 (8):1364-72. PMID: 12706933
  7. ↑ Arcavi L, Behar S, Caspi A, Reshef N, Boyko V, Knobler H (2004) High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study. Am Heart J 147 (2):239-45. DOI:10.1016/j.ahj.2003.09.013 PMID: 14760320
  8. ↑ Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R (2005) N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (7):666-75. DOI:10.1056/NEJMoa042330 PMID: 15716560
  9. ↑ Kléber AG (2000) ST-segment elevation in the electrocardiogram: a sign of myocardial ischemia. Cardiovasc Res 45 (1):111-8. PMID: 10728321
  10. ↑ Ashley EA, Myers J, Froelicher V (2000) Exercise testing in clinical medicine. Lancet 356 (9241):1592-7. DOI:10.1016/S0140-6736(00)03138-X PMID: 11075788
  11. ↑ Elamin MS, Boyle R, Kardash MM, Smith DR, Stoker JB, Whitaker W et al. (1982) Accurate detection of coronary heart disease by new exercise test. Br Heart J 48 (4):311-20. PMID: 6127094
  12. ↑ Mark DB, Shaw L, Harrell FE, Hlatky MA, Lee KL, Bengtson JR et al. (1991) Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 325 (12):849-53. DOI:10.1056/NEJM199109193251204 PMID: 1875969
  13. ↑ Chakko S, Woska D, Martinez H, de Marchena E, Futterman L, Kessler KM et al. (1991) Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 90 (3):353-9. PMID: 1825901
  14. ↑ Hemingway H, Shipley M, Christie D, Marmot M (1998) Cardiothoracic ratio and relative heart volume as predictors of coronary heart disease mortality. The Whitehall study 25 year follow-up. Eur Heart J 19 (6):859-69. PMID: 9651709
  15. ↑ Shaw LJ, Hachamovitch R, Redberg RF (2000) Current evidence on diagnostic testing in women with suspected coronary artery disease: choosing the appropriate test. Cardiol Rev 8 (1):65-74. PMID: 11174875
  16. ↑ Vigna C, Stanislao M, De Rito V, Russo A, Santoro T, Fusilli S et al. (2006) Inaccuracy of dipyridamole echocardiography or scintigraphy for the diagnosis of coronary artery disease in patients with both left bundle branch block and left ventricular dysfunction. Int J Cardiol 110 (1):116-8. DOI:10.1016/j.ijcard.2005.05.068 PMID: 16002158
  17. ↑ Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ et al. (1997) ACC/AHA guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. J Am Coll Cardiol 29 (4):862-79. PMID: 9091535
  18. ↑ Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS (1995) Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation 92 (8):2157-62. PMID: 7554196
  19. ↑ Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM et al. (2007) ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 49 (3):378-402. DOI:10.1016/j.jacc.2006.10.001 PMID: 17239724
  20. ↑ Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15 (4):827-32. PMID: 2407762
  21. ↑ Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF (2001) Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103 (3):415-22. PMID: 11157694
  22. ↑ Kerwin W, Hooker A, Spilker M, Vicini P, Ferguson M, Hatsukami T et al. (2003) Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 107 (6):851-6. PMID: 12591755
  23. ↑ Wasserman BA, Smith WI, Trout HH, Cannon RO, Balaban RS, Arai AE (2002) Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging initial results. Radiology 223 (2):566-73. PMID: 11997569
  24. ↑ Noto TJ, Johnson LW, Krone R, Weaver WF, Clark DA, Kramer JR et al. (1991) Cardiac catheterization 1990: a report of the Registry of the Society for Cardiac Angiography and Interventions (SCA&I). Cathet Cardiovasc Diagn 24 (2):75-83. PMID: 1742788
  25. ↑ 25.0 25.1 25.2 Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., Kazi, D. S., Kolte, D., Kumbhani, D. J., LoFaso, J., Mahtta, D., Mark, D. B., Minissian, M., Navar, A. M., Patel, A. R., … Peer Review Committee Members. (2023). 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of Patients With Chronic Coronary Disease: A report of the American heart association/American college of cardiology joint committee on clinical practice guidelines. Circulation, 148(9), e9–e119. https://doi.org/10.1161/CIR.0000000000001168
  26. ↑ 26.0 26.1 26.2 Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., Chieffo, A., Christodorescu, R. M., Deaton, C., Doenst, T., Jones, H. W., Kunadian, V., Mehilli, J., Milojevic, M., Piek, J. J., … ESC Scientific Document Group. (2024). 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal, 45(36), 3415–3537. https://doi.org/10.1093/eurheartj/ehae177
  27. ↑ 27.00 27.01 27.02 27.03 27.04 27.05 27.06 27.07 27.08 27.09 27.10 27.11 27.12 27.13 27.14 Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS (August 2023). "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol. 82 (9): 833–955. doi:10.1016/j.jacc.2023.04.003. PMID 37480922 Check |pmid= value (help).
  28. ↑ 28.00 28.01 28.02 28.03 28.04 28.05 28.06 28.07 28.08 28.09 28.10 28.11 28.12 28.13 28.14 Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S (September 2024). "2024 ESC Guidelines for the management of chronic coronary syndromes". Eur Heart J. 45 (36): 3415–3537. doi:10.1093/eurheartj/ehae177. PMID 39210710 Check |pmid= value (help).
  29. ↑ 29.0 29.1 29.2 Winchester DE, Cibotti-Sun M (August 2023). "2023 Chronic Coronary Disease Guideline-at-a-Glance". J Am Coll Cardiol. 82 (9): 956–960. doi:10.1016/j.jacc.2023.06.006. PMID 37480921 Check |pmid= value (help).
  30. ↑ Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (7329):71-86. PMID: 11786451
  31. ↑ Kaufmann PA, Mandinov L, Seiler C, Hess OM (2000) Impact of exercise-induced coronary vasomotion on anti-ischemic therapy. Coron Artery Dis 11 (4):363-9. PMID: 10860181
  32. ↑ Thadani U, Lipicky RJ (1994) Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 8 (4):611-23. PMID: 7848896
  33. ↑ Parker JD, Parker JO (1998) Nitrate therapy for stable angina pectoris. N Engl J Med 338 (8):520-31. DOI:10.1056/NEJM199802193380807 PMID: 9468470
  34. ↑ 34.0 34.1 Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999)guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).Circulation 99 (21):2829-48. PMID: 10351980
  35. ↑ Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA et al. (1994) Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST) Circulation 90 (2):762-8. PMID: 8044945
  36. ↑ 36.0 36.1 Savonitto S, Ardissino D (1998) Selection of drug therapy in stable angina pectoris. Cardiovasc Drugs Ther 12 (2):197-210. PMID: 9652879
  37. ↑ 37.0 37.1 Thadani U (1999) Treatment of stable angina. Curr Opin Cardiol 14 (4):349-58. PMID: 10448616
  38. ↑ (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 (14):801-7. DOI:10.1056/NEJM198104023041401 PMID: 7010157
  39. ↑ Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 107 (1):149-58.[1] PMID: 12515758
  40. ↑ Karlson BW, Emanuelsson H, Herlitz J, Nilsson JE, Olsson G (1991) Evaluation of the antianginal effect of nifedipine: influence of formulation dependent pharmacokinetics. Eur J Clin Pharmacol 40 (5):501-6. PMID: 1884725
  41. ↑ Waters D (1991) Proischemic complications of dihydropyridine calcium channel blockers. Circulation 84 (6):2598-600. PMID: 1959210
  42. ↑ Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al. (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292 (18):2217-25. DOI:10.1001/jama.292.18.2217 PMID: 15536108
  43. ↑ Markham A, Plosker GL, Goa KL (2000) Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 60 (4):955-74. PMID: 11085202
  44. ↑ (2003) Nicorandil for angina--an update. Drug Ther Bull 41 (11):86-8. PMID: 14658416
  45. ↑ 45.0 45.1 Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F; et al. (2006). "Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology". Eur Heart J. 27 (11): 1341–81. doi:10.1093/eurheartj/ehl001. PMID 16735367.
  46. ↑ 46.0 46.1 46.2 Williams MS, Levine GN, Kalra D, Agarwala A, Baptiste D, Cigarroa JE, Diekemper RL, Foster MV, Gulati M, Henry TD, Itchhaporia D, Lawton JS, Newby LK, Rogers KC, Soni K, Tamis-Holland JE (July 2025). "2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures". J Am Coll Cardiol. 85 (25): 2504–2535. doi:10.1016/j.jacc.2025.02.001. PMID 40310322 Check |pmid= value (help).
  47. ↑ Kaski JC, Rosano G, Gavrielides S, Chen L (1994) Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 23 (3):652-7. PMID: 8113548
  48. ↑ van den Heuvel AF, Dunselman PH, Kingma T, Verhorst P, Boomsma F, van Gilst WH et al. (2001) Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. J Am Coll Cardiol 37 (2):470-4. PMID: 11216965
  49. ↑ 49.0 49.1 49.2 Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J et al. (2007)2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 116 (23):2762-72.[2] PMID: 17998462
  50. ↑ Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL et al. (2007) Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115 (21):2761-88. DOI:10.1161/CIRCULATIONAHA.107.183885 PMID: 17502569
  51. ↑ (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 (8934):1383-9. PMID: 7968073
  52. ↑ Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (9493):1267-78. DOI:10.1016/S0140-6736(05)67394-1 PMID: 16214597
  53. ↑ LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (14):1425-35. DOI:10.1056/NEJMoa050461 PMID: 15755765
  54. ↑ 54.0 54.1 54.2 54.3 54.4 54.5 Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA (January 2022). "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 145 (3): e18–e114. doi:10.1161/CIR.0000000000001038. PMID 34882435 Check |pmid= value (help).
  55. ↑ Moliterno DJ, Elliott JM (1995) Randomized trials of myocardial revascularization. Curr Probl Cardiol 20 (3):125-90. PMID: 7600846
  56. ↑ Xaplanteris P, Fournier S, Pijls NH, Fearon WF, Barbato E, Tonino PA, Engstrøm T, Kääb S, Dambrink JH, Rioufol G, Toth GG, Piroth Z, Witt N, Fröbert O, Kala P, Linke A, Jagic N, Mates M, Mavromatis K, Samady H, Irimpen A, Oldroyd K, Campo G, Rothenbühler M, Jüni P, De Bruyne B (July 2018). "Five-Year Outcomes with PCI Guided by Fractional Flow Reserve". N Engl J Med. 379 (3): 250–259. doi:10.1056/NEJMoa1803538. PMID 29785878.
  57. ↑ Collet C, Mahendiran T, Fearon WF, Mizukami T, Munhoz D, Pijls NH, Tonino PA, Barbato E, Piroth Z, Sreckovic M, Thiele H, El Farissi M, Witt N, Rioufol G, Kala P, Engstrøm T, Mavromatis K, Fröbert O, Verlee P, Brunner S, Mates M, Jagic N, Campo G, Pardaens S, Ikeda K, Pereira TV, da Costa BR, Fournier S, De Bruyne B, Jüni P (January 2026). "Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial". Nat Med. 32 (1): 318–324. doi:10.1038/s41591-025-04132-5. PMID 41540107 Check |pmid= value (help).
  58. ↑ Smith SC, Feldman TE, Hirshfeld JW, Jacobs AK, Kern MJ, King SB et al. (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (1):e1-121. DOI:10.1016/j.jacc.2005.12.001 PMID: 16386656
  59. ↑ Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene AD et al. (1995) The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol 26 (7):1600-5. DOI:10.1016/0735-1097(95)00384-3 PMID: 7594092
  60. ↑ Hueb W, Soares PR, Gersh BJ, César LA, Luz PL, Puig LB et al. (2004) The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 43 (10):1743-51. DOI:10.1016/j.jacc.2003.08.065 PMID: 15145093
  61. ↑ 61.0 61.1 Kim MC, Kini A, Sharma SK (2002) Refractory angina pectoris: mechanism and therapeutic options. J Am Coll Cardiol 39 (6):923-34. PMID: 11897431
  62. ↑ Burkhoff D, Schmidt S, Schulman SP, Myers J, Resar J, Becker LC et al. (1999) Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial. ATLANTIC Investigators. Angina Treatments-Lasers and Normal Therapies in Comparison. Lancet 354 (9182):885-90. PMID: 10489946
  63. ↑ Urano H, Ikeda H, Ueno T, Matsumoto T, Murohara T, Imaizumi T (2001) Enhanced external counterpulsation improves exercise tolerance, reduces exercise-induced myocardial ischemia and improves left ventricular diastolic filling in patients with coronary artery disease. J Am Coll Cardiol 37 (1):93-9. PMID: 11153780
  64. ↑ Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS (August 2023). "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines". Circulation. 148 (9): e9–e119. doi:10.1161/CIR.0000000000001168. PMID 37471501 Check |pmid= value (help).
  65. ↑ Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, Taylor RS (February 2023). "Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis". Eur Heart J. 44 (6): 452–469. doi:10.1093/eurheartj/ehac747. PMC 9902155 Check |pmc= value (help). PMID 36746187 Check |pmid= value (help).
  66. ↑ Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA (January 2022). "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol. 79 (2): e21–e129. doi:10.1016/j.jacc.2021.09.006. PMID 34895950 Check |pmid= value (help).
  67. ↑ Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL, de Lemos JA, DeWald TA, Elgendy IY, Feldman DN, Goyal A, Isiadinso I, Menon V, Morrow DA, Mukherjee D, Platz E, Promes SB, Sandner S, Sandoval Y, Schunder R, Shah B, Stopyra JP, Talbot AW, Taub PR, Williams MS (April 2025). "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 151 (13): e771–e862. doi:10.1161/CIR.0000000000001309. PMID 40014670 Check |pmid= value (help).
  68. ↑ Thomas RJ, Beatty AL, Beckie TM, Brewer LC, Brown TM, Forman DE, Franklin BA, Keteyian SJ, Kitzman DW, Regensteiner JG, Sanderson BK, Whooley MA (July 2019). "Home-Based Cardiac Rehabilitation: A Scientific Statement From the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology". Circulation. 140 (1): e69–e89. doi:10.1161/CIR.0000000000000663. PMID 31082266.
  69. ↑ Brown TM, Pack QR, Aberegg E, Brewer LC, Ford YR, Forman DE, Gathright EC, Khadanga S, Ozemek C, Thomas RJ (October 2024). "Core Components of Cardiac Rehabilitation Programs: 2024 Update: A Scientific Statement From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation". Circulation. 150 (18): e328–e347. doi:10.1161/CIR.0000000000001289. PMID 39315436 Check |pmid= value (help).
  70. ↑ Centers for Disease Control (CDC) (1989) The Surgeon General's 1989 Report on Reducing the Health Consequences of Smoking: 25 Years of Progress. MMWR Morb Mortal Wkly Rep 38 Suppl 2 ():1-32. PMID: 2494426
  71. ↑ 71.0 71.1 Benowitz NL, Gourlay SG (1997) Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 29 (7):1422-31. PMID: 9180099
  72. ↑ Bartecchi CE, MacKenzie TD, Schrier RW (1994) The human costs of tobacco use (1) N Engl J Med 330 (13):907-12. DOI:10.1056/NEJM199403313301307 PMID: 8114863
  73. ↑ MacKenzie TD, Bartecchi CE, Schrier RW (1994) The human costs of tobacco use (2) N Engl J Med 330 (14):975-80. DOI:10.1056/NEJM199404073301406 PMID: 8121461
  74. ↑ Critchley J, Capewell S (2003) Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev (4):CD003041. DOI:10.1002/14651858.CD003041 PMID: 14583958
  75. ↑ Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P (1998) Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc Drugs Ther 12 (3):239-44. PMID: 9784902
  76. ↑ (1994) Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. Arch Intern Med 154 (9):989-95. PMID: 8179456
  77. ↑ Dudina A, Cooney MT, De Bacquer D, De Backer G, Ducimetière P, Jousilahti P et al. (2011) Relationships between body mass index, cardiovascular mortality, and risk factors: a report from the SCORE investigators. Eur J Cardiovasc Prev Rehabil ():. DOI:10.1177/1741826711412039 PMID: 21642320
  78. ↑ 78.0 78.1 Smith GD, Shipley MJ, Marmot MG, Rose G (1992) Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 267 (1):70-6. PMID: 1727199
  79. ↑ (1992) Long-term comprehensive care of cardiac patients. Recommendations by the Working Group on Rehabilitation of the European Society of Cardiology. Eur Heart J 13 Suppl C ():1-45. PMID: 1639095
  80. ↑ 80.0 80.1 80.2 De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24 (17):1601-10. PMID: 12964575
  81. ↑ (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354 (9177):447-55. PMID: 10465168
  82. ↑ Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R et al. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105 (16):1897-903. PMID: 11997274
  83. ↑ Bucher HC, Hengstler P, Schindler C, Meier G (2002) N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112 (4):298-304. PMID: 11893369
  84. ↑ Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC (2005) Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 165 (7):725-30. DOI:10.1001/archinte.165.7.725 PMID: 15824290
  85. ↑ Kris-Etherton PM, Harris WS, Appel LJ, Nutrition Committee (2003) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 23 (2):e20-30. PMID: 12588785
  86. ↑ He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR et al. (2004) Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 109 (22):2705-11. DOI:10.1161/01.CIR.0000132503.19410.6B PMID: 15184295
  87. ↑ 87.0 87.1 European Society of Hypertension-European Society of Cardiology Guidelines Committee (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (6):1011-53. DOI:10.1097/01.hjh.0000059051.65882.32 PMID: 12777938
  88. ↑ American Diabetes Association (2003) Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 Suppl 1 ():S33-50. PMID: 12502618
  89. ↑ Inzucchi SE, Amatruda JM (2003) Lipid management in patients with diabetes: translating guidelines into action. Diabetes Care 26 (4):1309-11. PMID: 12663615
  90. ↑ Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (5):383-93. DOI:10.1056/NEJMoa021778 PMID: 12556541

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Chronic_stable_angina_overview&oldid=1744051"